Evidence mapPaperPMID 39168095Full record

Trial reportCell reports. Medicine2024

Camu-camu decreases hepatic steatosis and liver injury markers in overweight, hypertriglyceridemic individuals: A randomized crossover trial.

Anne-Laure Agrinier, Arianne Morissette, Laurence Daoust, Théo Gignac, Julie Marois, Thibault V Varin, Geneviève Pilon, Éric Larose, Claudia Gagnon, Yves Desjardins and 4 more

Abstract readRandomized Controlled Trial
In one paragraph

Trial report in Cell reports. Medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed.

  1. Review
  2. Review
  3. Mechanistic insights into natural product-driven modulation of NLRP3-inflammasome signalling in metabolic syndrome.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2026
    Review
  4. Review
  5. Review
  6. Review
  7. Article
  8. Article
  9. Review
  10. Review
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Anne-Laure AgrinierDepartment of Medicine, Faculty of Medicine, Québec Heart and Lung Institute (IUCPQ), Université Laval, Quebec City, QC, Canada; Centre Nutrition, santé et société (NUTRISS), Institute of Nutrition and Functional Foods (INAF), Université Laval, Quebec City, QC, Canada.
Arianne MorissetteDepartment of Medicine, Faculty of Medicine, Québec Heart and Lung Institute (IUCPQ), Université Laval, Quebec City, QC, Canada; Centre Nutrition, santé et société (NUTRISS), Institute of Nutrition and Functional Foods (INAF), Université Laval, Quebec City, QC, Canada.
Laurence DaoustDepartment of Medicine, Faculty of Medicine, Québec Heart and Lung Institute (IUCPQ), Université Laval, Quebec City, QC, Canada; Centre Nutrition, santé et société (NUTRISS), Institute of Nutrition and Functional Foods (INAF), Université Laval, Quebec City, QC, Canada.
Théo GignacDepartment of Medicine, Faculty of Medicine, Centre de Recherche CHU de Québec-Université Laval, Université Laval, Quebec City, QC, Canada.
Julie MaroisCentre Nutrition, santé et société (NUTRISS), Institute of Nutrition and Functional Foods (INAF), Université Laval, Quebec City, QC, Canada.
Thibault V VarinCentre Nutrition, santé et société (NUTRISS), Institute of Nutrition and Functional Foods (INAF), Université Laval, Quebec City, QC, Canada.
Geneviève PilonDepartment of Medicine, Faculty of Medicine, Québec Heart and Lung Institute (IUCPQ), Université Laval, Quebec City, QC, Canada; Centre Nutrition, santé et société (NUTRISS), Institute of Nutrition and Functional Foods (INAF), Université Laval, Quebec City, QC, Canada.
Éric LaroseDepartment of Medicine, Faculty of Medicine, Québec Heart and Lung Institute (IUCPQ), Université Laval, Quebec City, QC, Canada.
Claudia GagnonDepartment of Medicine, Faculty of Medicine, Québec Heart and Lung Institute (IUCPQ), Université Laval, Quebec City, QC, Canada; Department of Medicine, Faculty of Medicine, Centre de Recherche CHU de Québec-Université Laval, Université Laval, Quebec City, QC, Canada.
Yves DesjardinsCentre Nutrition, santé et société (NUTRISS), Institute of Nutrition and Functional Foods (INAF), Université Laval, Quebec City, QC, Canada; Department of Plant Science, Faculty of Agriculture and Food sciences, Université Laval, Quebec City, QC, Canada.
Fernando F AnhêDepartment of Medicine, Faculty of Medicine, Québec Heart and Lung Institute (IUCPQ), Université Laval, Quebec City, QC, Canada; Centre Nutrition, santé et société (NUTRISS), Institute of Nutrition and Functional Foods (INAF), Université Laval, Quebec City, QC, Canada.
Anne-Marie CarreauDepartment of Medicine, Faculty of Medicine, Centre de Recherche CHU de Québec-Université Laval, Université Laval, Quebec City, QC, Canada.
Marie-Claude VohlCentre Nutrition, santé et société (NUTRISS), Institute of Nutrition and Functional Foods (INAF), Université Laval, Quebec City, QC, Canada; School of Nutrition, Université Laval, Quebec City, QC, Canada.
André MaretteDepartment of Medicine, Faculty of Medicine, Québec Heart and Lung Institute (IUCPQ), Université Laval, Quebec City, QC, Canada; Centre Nutrition, santé et société (NUTRISS), Institute of Nutrition and Functional Foods (INAF), Université Laval, Quebec City, QC, Canada. Electronic address: andre.marette@criucpq.ulaval.ca.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Non-alcoholic fatty liver disease (NAFLD) affects 25% of the adult population with no effective drug treatments available. Previous animal studies reported that a polyphenol-rich extract from the Amazonian berry camu-camu (CC) prevented hepatic steatosis in a mouse model of diet-induced obesity. This study aims to determine the impact of CC on hepatic steatosis (primary outcome) and evaluate changes in metabolic and gut microbiota profiles (exploratory outcomes). A randomized, double-blind, placebo-controlled crossover trial is conducted on 30 adults with overweight and hypertriglyceridemia, who consume 1.5 g of CC capsules or placebo daily for 12 weeks. CC treatment decreases liver fat by 7.43%, while it increases by 8.42% during the placebo intervention, showing a significant difference of 15.85%. CC decreases plasma aspartate and alanine aminotransferases levels and promotes changes in gut microbiota composition. These findings support that polyphenol-rich prebiotic may reduce liver fat in adults with overweight, reducing the risk of developing NAFLD.

Indexed as

LiverMyrtaceaeNon-alcoholic Fatty Liver DiseasePhytotherapyPlant PreparationsAdultAlanine TransaminaseBiomarkersCross-Over StudiesDouble-Blind MethodFemaleGastrointestinal MicrobiomeHumansHypertriglyceridemiaMaleMiddle AgedAlanine TransaminaseBiomarkersPlant Preparationsaminotransferasescamu-camugut microbiotanon-alcoholic fatty liver diseasepolyphenols

Identifiers

PMID39168095
PMCPMC11384942

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.